Insider Selling: Martine Rothblatt Sells 3,833 Shares of United Therapeutics Corp. Stock (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine Rothblatt sold 3,833 shares of United Therapeutics Corp. stock on the open market in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $84.20, for a total value of $322,738.60. Following the completion of the sale, the chief executive officer now directly owns 140 shares of the company’s stock, valued at approximately $11,788. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Corp. (NASDAQ:UTHR) traded up 0.96% during mid-day trading on Friday, hitting $85.48. The stock had a trading volume of 547,741 shares. United Therapeutics Corp. has a 52-week low of $44.51 and a 52-week high of $85.92. The stock’s 50-day moving average is $76.23 and its 200-day moving average is $68.75. The company has a market cap of $4.267 billion and a P/E ratio of 14.60.
United Therapeutics Corp. (NASDAQ:UTHR) last issued its quarterly earnings data on Thursday, July 25th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.05. The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $250.17 million. During the same quarter in the previous year, the company posted $1.34 earnings per share. The company’s revenue for the quarter was up 24.4% on a year-over-year basis.
A number of analysts have recently weighed in on UTHR shares. Analysts at Goldman Sachs Group Inc. raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $55.00 to $56.00 in a research note to investors on Wednesday, September 18th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics Corp. (NASDAQ:UTHR) in a research note to investors on Thursday, September 12th. They now have a $81.00 price target on the stock. Finally, analysts at Argus raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $75.00 to $85.00 in a research note to investors on Monday, August 5th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and one has assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $64.20.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.